Mayo Clinic Launches First Trial of Low-Dose Radiation to Slow Parkinson's Disease

Mayo Clinic researchers have launched the first clinical trial using low-dose radiation to treat early-stage Parkinson's disease, aiming to slow the condition by calming brain inflammation rather than just managing symptoms. The trial will test whether a five-day course of targeted radiation can fundamentally alter the disease's underlying biology.[1][2][5]

Parkinson's disease is traditionally managed with dopamine-replacing medications or deep brain stimulation, which address the movement symptoms but do not stop the progressive loss of brain cells. This new approach pivots to the immune system, testing if radiation—typically used at high doses to destroy cancer—can act as a localized anti-inflammatory agent.[1][2]

The Rochester, Minnesota-based study, launching in late 2026, will enroll 20 patients between the ages of 45 and 75 who have early-stage Parkinson's without a known genetic cause. Participants will undergo a 10- to 15-minute radiation session for five consecutive days, utilizing the same linear accelerators normally reserved for tumor ablation.[1][2]

Repurposing Radiation

"This is very different from using radiation to damage or destroy tissue," said Dr. Yasamin Sharifzadeh, a Mayo Clinic radiation oncologist and the trial's principal investigator. "We're using a much lower dose. The goal is not to destroy brain tissue but to investigate whether radiation can reduce inflammatory processes in specific parts of the brain."[1][5]

High-dose radiation shatters DNA to kill tumor cells, but low-dose radiation has historically demonstrated paradoxical anti-inflammatory effects. For decades, doctors in parts of Europe have used ultra-low-dose radiation to calm painful, swollen joints in people with osteoarthritis when standard medications fail, a principle the Mayo team is now applying to neurodegeneration.[1][3]

Before any radiation is delivered, researchers will use advanced brain imaging, including standard MRI and specialized dopamine transporter scans, to map each participant's unique anatomy. This ensures the micro-doses are delivered strictly to the specific neural circuits where abnormal proteins and inflammation are actively driving cell death.[1][2][3]

During the procedure, patients will wear a custom-fitted protective mesh mask to keep their head perfectly still beneath the linear accelerator. Using dynamic conformal arc therapy, the machine will rotate smoothly around the head to shape the ultra-low-dose beams so they converge only on the pre-mapped target areas.[1][3][5]

To measure success, researchers will not rely solely on clinical observation of motor symptoms. They will track inflammatory biomarkers in the blood and use imaging to monitor protein accumulation and dopamine levels at six hours post-treatment, followed by comprehensive evaluations at three, six, and 12 months.[1][2]

The Inflammation Hypothesis

The scientific consensus around Parkinson's has increasingly recognized neuroinflammation as a primary driver of the disease, rather than just a byproduct. As abnormal alpha-synuclein proteins clump together, the brain's resident immune cells, called microglia, become chronically activated and begin to attack the surrounding tissue.[1][5]

This chronic microglial activation creates a toxic environment that accelerates the death of dopamine-producing neurons in the substantia nigra. By attempting to quiet this immune response with radiation, the trial aims to break the cycle of cell death and preserve the remaining dopamine reserves for as long as possible.[1][2]

"Parkinson's disease is not a single uniform condition but rather a collection of related disease subtypes that may differ biologically," noted Dr. Rodolfo Savica, a Mayo Clinic neurologist and study investigator. "This diversity complicates the search for a universal treatment, but despite this complication, inflammation appears to play a meaningful role across many forms of the disease."[1][5]

The decision to restrict the trial to patients without a known genetic cause of Parkinson's is deliberate. Idiopathic Parkinson's, which accounts for roughly 85 to 90 percent of all cases, is heavily associated with this inflammatory cascade, making these patients the most likely to benefit from an immune-modulating intervention.[1][2]

Existing therapies, such as levodopa, effectively replace missing dopamine to restore motor function, but their efficacy wanes over time as more neurons die. Surgical interventions like focused ultrasound or deep brain stimulation also target symptom relief, leaving the underlying inflammatory cascade completely unchecked.[1][2]

Establishing Safety

For patients currently navigating a Parkinson's diagnosis, this trial represents a conceptual shift but not an immediate treatment option. With just 20 participants and no placebo control group, the study is an early proof of concept rather than a proven therapy ready for the clinic.[1][3]

The primary hurdle for this pioneering phase of research is establishing safety, as exposing the brain to any level of radiation carries theoretical long-term risks. The 12-month follow-up period is designed to gather foundational biological evidence and ensure that the anti-inflammatory benefits outweigh any potential collateral damage.[1][3]

Blood samples drawn throughout the year-long observation window will allow researchers to quantify the systemic immune response. By correlating these fluid biomarkers with the advanced imaging data, the team hopes to build a comprehensive picture of how the brain's inflammatory environment shifts in response to the radiation.[1][2]

If the initial 20-person cohort demonstrates a measurable drop in inflammatory biomarkers without severe adverse effects, the protocol will likely expand into larger, multi-center trials. For now, the medical community is watching to see if an oncology staple can be safely recalibrated to protect the brain rather than ablate it.[1][2]

The implications of a successful trial could extend well beyond Parkinson's disease. If targeted low-dose radiation proves effective at calming microglial activation, researchers may eventually explore similar protocols for other neuroinflammatory conditions, including Alzheimer's disease and certain forms of dementia.[2][3]